WO2003026621A2 - Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs notamment de gout et produit obtenu - Google Patents
Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs notamment de gout et produit obtenu Download PDFInfo
- Publication number
- WO2003026621A2 WO2003026621A2 PCT/FR2002/003205 FR0203205W WO03026621A2 WO 2003026621 A2 WO2003026621 A2 WO 2003026621A2 FR 0203205 W FR0203205 W FR 0203205W WO 03026621 A2 WO03026621 A2 WO 03026621A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical product
- administered orally
- manufacturing
- chosen
- taste
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
Definitions
- the present invention relates to the manufacture of pharmaceutical products administered orally, in particular in the form of tablets, capsules or soft capsules with polarizing agents.
- the invention also covers the product obtained.
- Certain pharmaceutical products can be administered to people without their knowledge in order to make them lose or at the very least limit their reaction capacities.
- the administrator by a diverted use of the drug can indulge in abuses, the person under the influence of these drugs becoming a victim.
- active principles having sedative, hypnotic or anxiolytic actions which are prescribed for certain ailments relating in particular to sleep disorders. We can cite :
- Xanax One of these benzodiazepines, f lunitrazepam, is marketed under the name Narcozep.
- Administration is notably carried out by incorporating one or more of these products into the drink or food intended for the victim.
- the incorporation of one or more of these drugs goes unnoticed.
- the purpose of the present invention is to provide a method of manufacturing a pharmaceutical product, indicated for the oral route which overcomes these risks of hidden administration.
- a pharmaceutical product indicated for the oral route which overcomes these risks of hidden administration.
- the invention of the prior art provides for adding constituents which, if the composition is introduced into an aqueous drink generate visual means making it possible to attract the attention of the consumer.
- constituents expressly indicated include dyes released during the introduction into the aqueous drink and an effervescent couple which causes the tablet to float almost instantaneously.
- these means of attracting attention are only visual means which remain insufficient when the potential victim is in a place with low light.
- the tablets thus produced are produced in two layers, one containing the active ingredient and the other the dyes.
- the object of the present invention is to remedy these shortcomings and to propose a process for the manufacture of a pharmaceutical form containing taste-promoting agents, associated with fluorescent substances in order to be able to attract the attention of the victims even in the dark or even when the visual marks were not appreciated before tasting the drink.
- the method makes it possible to obtain a product immediately recognizable by the one to whom it is administered during diverted use, for example by introducing the medicament into a drink or a food.
- the present method proposes to combine specific polarizing agents with sensitive pharmaceutical products such as hypnotics, sedatives or anxiolytics, presented in the form of tablets, capsules or gelatin capsules also called soft capsules for administration by orally.
- sensitive pharmaceutical products such as hypnotics, sedatives or anxiolytics
- Such agents remain imperceptible and ineffective as long as the forms are used orally.
- the keying agents according to the invention are only released in the event of misuse.
- tablette is intended to mean the tablets obtained from powders subjected to strong compression, the capsules regardless of the method of manufacture and the capsules regardless of the consistency.
- At least one fluorescent polarizing agent is made up of a bitter substance.
- taste-neutralizing agents made up of a bitter substance mention may be made of natural derivatives such as aloe tincture, quinine extracts, bitter products marketed under the name of Bitrex, which are derivatives of denatonium benzoate, added at concentrations between 0.01 and 2.00%. Mention may also be made of any substance with a flavor-enhancing character which reinforces the impression of bitterness, such as glutamic acid, sodium chloride or potassium chloride which can be added in concentrations of between 0.1 and 15.00 %.
- a taste-releasing agent releasing insoluble particles, floating on the surface of the drink and easily recognizable in the mouth, mention may be made of vegetable charcoal derivatives or any other substance whose density is less than 1, added at concentrations of between 1 and 10%.
- Other polarizing agents which form gelled globules, also easily recognizable in the mouth, can be chosen from derivatives of the class of carbomers which are polymers of acrylic acid, at concentrations of between 5 and 50%. Mention may also be made of carbomethylcellulose, dextrans, alginic acid.
- Such fluorescent substances are preferably chosen from f luorescein, dextran grafted with f luorescein, tetracyclines, riboflavin added at concentrations of between 0.1 and 5.0%.
- the coloring agent when the tablet is introduced into the beverage or food, the coloring agent then released significantly changes the final color of the beverage, which can help attract the attention of the consumer.
- Example 1 film-coated tablet
- the 100 mg tablet in this case is then coated with a suspension of titanium oxide in an ethylcellulose solution.
- Example 2 Denatonium benzoate capsule lmg Fluorescein l g Erythrosine lmg Vegetable carbon) 3 mg
- Polyvinyl acid (Carbopol 5984) 5 mg Mannitol 87 mg Active ingredient f lunitrazepam mg Packaged in a size 2 capsule.
- the polarizing agents are not released and thus the sensations at the level of taking are equivalent to those of the drug without agents.
- the agents are released leading to react the person either by fluorescence or by taste as soon as a fraction of the drink is absorbed or food.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002347253A AU2002347253A1 (en) | 2001-09-21 | 2002-09-19 | Method for making an oral pharmaceutical product with tell-tale agents, in particular of taste and resulting product |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR01/12189 | 2001-09-21 | ||
FR0112189A FR2829932B1 (fr) | 2001-09-21 | 2001-09-21 | Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs et produit obtenu |
FR0202514A FR2829933B3 (fr) | 2001-09-21 | 2002-02-28 | Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs notamment de gout et produit obtenu |
FR02/02514 | 2002-02-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003026621A2 true WO2003026621A2 (fr) | 2003-04-03 |
WO2003026621A3 WO2003026621A3 (fr) | 2003-10-09 |
Family
ID=26213193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/003205 WO2003026621A2 (fr) | 2001-09-21 | 2002-09-19 | Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs notamment de gout et produit obtenu |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002347253A1 (fr) |
FR (1) | FR2829933B3 (fr) |
WO (1) | WO2003026621A2 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7588774B2 (en) | 2003-05-12 | 2009-09-15 | Becton, Dickinson And Company | Molecules enhancing dermal delivery of influenza vaccines |
FR2949062A1 (fr) * | 2009-08-12 | 2011-02-18 | Debregeas Et Associes Pharma | Nouvelles formulations pharmaceutiques contre le mesusage des medicaments |
WO2011107945A1 (fr) * | 2010-03-04 | 2011-09-09 | Cosmo Technologies Ltd. | Composition solide pour administration orale de colorants et ses applications en diagnostic |
US8529954B2 (en) | 2008-11-14 | 2013-09-10 | Debregeas Et Associes Pharma | Composition based on gamma-hydroxybutyric acid |
EP2591350B1 (fr) * | 2010-07-06 | 2016-10-26 | Ethypharm | Méthode et agent pour la détection de drogues dans les boisson |
EP2590632B1 (fr) * | 2010-07-06 | 2019-04-17 | Ethypharm | Forme pharmaceutique pour lutter contre la soumission chimique d'un medicament |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2873292B1 (fr) * | 2004-07-23 | 2008-05-30 | Jean Noel Colombani | Composes et methodes pour controler la prise d'alcool |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4789546A (en) * | 1987-02-19 | 1988-12-06 | Consumer Products Corp. | Multiple-layer tablet with contrasting organoleptic characteristics |
WO1995018596A1 (fr) * | 1994-01-04 | 1995-07-13 | Voss Gunter M | Procede de production de comprimes |
WO1995020947A1 (fr) * | 1994-02-01 | 1995-08-10 | Rhone-Poulenc Rorer Limited | Comprimes a l'epreuve d'un usage abusif |
GB2309166A (en) * | 1996-01-20 | 1997-07-23 | Cleansharp Ltd | Detecting mis-use of drugs |
GB2331702A (en) * | 1997-11-29 | 1999-06-02 | Venalink Ltd | Tablets containing a bitter excipient and/or a dye |
WO2000038649A1 (fr) * | 1998-12-23 | 2000-07-06 | Sanofi-Synthelabo | Composition pharmaceutique pour une administration par voie orale destinee a eviter le detournement d'usage au depens d'un tiers |
US6274555B1 (en) * | 2000-05-15 | 2001-08-14 | Lisa A. Berdami | Composition and method for topical animal medication |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6066953A (ja) * | 1983-09-21 | 1985-04-17 | Yamasa Shoyu Co Ltd | 苦味料 |
JPH11103814A (ja) * | 1997-09-30 | 1999-04-20 | Showa Sangyo Co Ltd | 苦味剤、味質改善剤、苦味付与または味質改善のための使用、および苦味を付与したか味質を改善した飲食品または薬品 |
JPH11335303A (ja) * | 1998-05-26 | 1999-12-07 | Lion Corp | 苦味増強方法及び皮膚外用剤 |
BR9802715C1 (pt) * | 1998-07-08 | 2005-10-18 | Foothills Ind E Com Ltda | Método de desnaturar produtos tóxicos e produtos tóxicos desnaturados obtidos |
JP2000026260A (ja) * | 1998-07-13 | 2000-01-25 | Earth Chem Corp Ltd | 口腔用組成物 |
-
2002
- 2002-02-28 FR FR0202514A patent/FR2829933B3/fr not_active Expired - Lifetime
- 2002-09-19 WO PCT/FR2002/003205 patent/WO2003026621A2/fr not_active Application Discontinuation
- 2002-09-19 AU AU2002347253A patent/AU2002347253A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4789546A (en) * | 1987-02-19 | 1988-12-06 | Consumer Products Corp. | Multiple-layer tablet with contrasting organoleptic characteristics |
WO1995018596A1 (fr) * | 1994-01-04 | 1995-07-13 | Voss Gunter M | Procede de production de comprimes |
WO1995020947A1 (fr) * | 1994-02-01 | 1995-08-10 | Rhone-Poulenc Rorer Limited | Comprimes a l'epreuve d'un usage abusif |
GB2309166A (en) * | 1996-01-20 | 1997-07-23 | Cleansharp Ltd | Detecting mis-use of drugs |
GB2331702A (en) * | 1997-11-29 | 1999-06-02 | Venalink Ltd | Tablets containing a bitter excipient and/or a dye |
WO2000038649A1 (fr) * | 1998-12-23 | 2000-07-06 | Sanofi-Synthelabo | Composition pharmaceutique pour une administration par voie orale destinee a eviter le detournement d'usage au depens d'un tiers |
US6274555B1 (en) * | 2000-05-15 | 2001-08-14 | Lisa A. Berdami | Composition and method for topical animal medication |
Non-Patent Citations (5)
Title |
---|
DATABASE WPI Section Ch, Week 200010 Derwent Publications Ltd., London, GB; Class B07, AN 2000-109329 XP002184678 & JP 11 335303 A (LION CORP), 7 décembre 1999 (1999-12-07) * |
DATABASE WPI Section Ch, Week 200016 Derwent Publications Ltd., London, GB; Class B05, AN 2000-176869 XP002184677 & JP 2000 026260 A (EARTH SEIYAKU KK), 25 janvier 2000 (2000-01-25) * |
DATABASE WPI Section Ch, Week 200045 Derwent Publications Ltd., London, GB; Class E14, AN 2000-499443 XP002184676 & BR 9 802 715 A (FOOTHILLS IND & COMERCIO LTDA), 4 juillet 2000 (2000-07-04) * |
PATENT ABSTRACTS OF JAPAN vol. 009, no. 196 (C-297), 13 août 1985 (1985-08-13) & JP 60 066953 A (YAMASA SHOYU KK), 17 avril 1985 (1985-04-17) * |
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 09, 30 juillet 1999 (1999-07-30) & JP 11 103814 A (SHOWA SANGYO CO LTD), 20 avril 1999 (1999-04-20) * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7588774B2 (en) | 2003-05-12 | 2009-09-15 | Becton, Dickinson And Company | Molecules enhancing dermal delivery of influenza vaccines |
US8529954B2 (en) | 2008-11-14 | 2013-09-10 | Debregeas Et Associes Pharma | Composition based on gamma-hydroxybutyric acid |
US8999392B2 (en) | 2009-08-12 | 2015-04-07 | Debregeas Et Associes Pharma | Pharmaceutical formulations to prevent the misuse of medicinal drugs |
FR2949062A1 (fr) * | 2009-08-12 | 2011-02-18 | Debregeas Et Associes Pharma | Nouvelles formulations pharmaceutiques contre le mesusage des medicaments |
CN102573801A (zh) * | 2009-08-12 | 2012-07-11 | D&A制药 | 防止药物滥用的新型药剂配方 |
WO2011018583A3 (fr) * | 2009-08-12 | 2011-04-07 | Debregeas Et Associes Pharma | Nouvelles formulations pharmaceutiques contre le mésusage des médicaments |
EA021856B1 (ru) * | 2009-08-12 | 2015-09-30 | Дебрежа Э Ассосье Фарма | Фармацевтические композиции для предотвращения злоупотребления лекарственными препаратами |
TWI465261B (zh) * | 2009-08-12 | 2014-12-21 | Debregeas Et Associes Pharma | 用以預防濫用藥物之新穎藥學調配物 |
US8545811B2 (en) | 2010-03-04 | 2013-10-01 | Cosmo Technologies Ltd. | Solid composition for the oral administration of dyes and diagnostic use thereof |
WO2011107945A1 (fr) * | 2010-03-04 | 2011-09-09 | Cosmo Technologies Ltd. | Composition solide pour administration orale de colorants et ses applications en diagnostic |
US9402923B2 (en) | 2010-03-04 | 2016-08-02 | Cosmo Technologies Inc. | Solid composition for the oral administration of dyes and diagnostic use thereof |
US9402922B2 (en) | 2010-03-04 | 2016-08-02 | Cosmo Technologies Inc. | Solid composition for the oral administration of dyes and diagnostic use thereof |
AU2011222496B2 (en) * | 2010-03-04 | 2016-08-18 | Cosmo Technologies Ltd. | Solid composition for the oral administration of dyes and diagnostic use thereof |
US10265420B2 (en) | 2010-03-04 | 2019-04-23 | Cosmo Technologies Ltd. | Solid composition for the oral administration of dyes and diagnostic use thereof |
EP2591350B1 (fr) * | 2010-07-06 | 2016-10-26 | Ethypharm | Méthode et agent pour la détection de drogues dans les boisson |
EP2590632B1 (fr) * | 2010-07-06 | 2019-04-17 | Ethypharm | Forme pharmaceutique pour lutter contre la soumission chimique d'un medicament |
Also Published As
Publication number | Publication date |
---|---|
FR2829933B3 (fr) | 2004-03-12 |
AU2002347253A1 (en) | 2003-04-07 |
FR2829933A1 (fr) | 2003-03-28 |
WO2003026621A3 (fr) | 2003-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2874967B2 (ja) | 本質的に水に不溶な薬剤活性体のための薬剤水懸濁液 | |
BE1019493A3 (fr) | Formulations. | |
CN102014904B (zh) | 具有适口味道的去铁酮液体配制品 | |
CA2663062A1 (fr) | Forme galenique pour l'administration par voie trans-muqueuse de principes actifs | |
EP2616046A1 (fr) | Système d'administration aqueux de médicament comportant un agent masquant une saveur désagréable | |
BE1019753A5 (fr) | Ameliorations de compositions pharmaceutiques, et relatives a celles-ci. | |
WO2006028632A1 (fr) | Laxatif a base de sels de phosphate aromatise a l'aspartame et au citrate | |
US10071064B2 (en) | Tincture for infusing flavonoids and methods of use | |
WO2003026621A2 (fr) | Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs notamment de gout et produit obtenu | |
FR2760639A1 (fr) | Association therapeutique mineralo-vitaminique sous forme de preparation unitaire liquide buvable | |
EP2591350B1 (fr) | Méthode et agent pour la détection de drogues dans les boisson | |
JP7006583B2 (ja) | タダラフィル経口フィルムを製造する方法 | |
FR2829932A1 (fr) | Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs et produit obtenu | |
CA2909750C (fr) | Composition pharmaceutique, dietetique ou alimentaire liquide ou semi-liquide depourvue d'amertume contenant un sel d'arginine | |
JP3884611B2 (ja) | 衝動性疾患の改善剤 | |
FR3102058A1 (fr) | Utilisation de NMN pour la prévention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes | |
CA2802404C (fr) | Forme pharmaceutique pour lutter contre la soumission chimique d'un medicament | |
Kpaibe et al. | Stabilité des suspensions reconstituées de la combinaison thérapeutique antipaludique à base d’artéméther-luméfantrine avec différents types d’eaux | |
FR2967332A1 (fr) | Solution aqueuse de phytine et utilisation de ladite solution pour la preparation d'un complement alimentaire liquide ou d'une composition cosmetique | |
US20030219432A1 (en) | Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages | |
Singh et al. | Himanshu Chaurasiya | |
BE1021980B1 (fr) | Composition amincissante. | |
CA3143343A1 (fr) | Composition stimulante et procede pour la preparer | |
CN112716897A (zh) | 一种含纳米级大麻二酚的高度酒精饮料及其制备方法 | |
Dukes | Drugs used in non-orthodox medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |